IO Biotech Inc
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand … Read more
IO Biotech Inc (IOBT) - Total Liabilities
Latest total liabilities as of September 2025: $39.05 Million USD
Based on the latest financial reports, IO Biotech Inc (IOBT) has total liabilities worth $39.05 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
IO Biotech Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how IO Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
IO Biotech Inc Competitors by Total Liabilities
The table below lists competitors of IO Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Glunz & Jensen
CO:GJ
|
Denmark | Dkr112.10 Million |
|
Bank Mnc Internasional Tbk
JK:BABP
|
Indonesia | Rp17.35 Trillion |
|
Asuransi Kresna Mitra Tbk PT
JK:ASMI
|
Indonesia | Rp1.05 Trillion |
|
CaliberCos Inc. Class A Common Stock
NASDAQ:CWD
|
USA | $73.28 Million |
|
Welspun Investments and Commercials Limited
NSE:WELINV
|
India | ₹909.56 Million |
|
BWYS Group Berhad
KLSE:0313
|
Malaysia | RM205.32 Million |
|
Inter-M Corporation
KQ:017250
|
Korea | ₩49.66 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down IO Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 42.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.98 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IO Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IO Biotech Inc (2019–2024)
The table below shows the annual total liabilities of IO Biotech Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $20.68 Million | +17.82% |
| 2023-12-31 | $17.56 Million | +35.56% |
| 2022-12-31 | $12.95 Million | +24.96% |
| 2021-12-31 | $10.36 Million | +239.80% |
| 2020-12-31 | $3.05 Million | -72.00% |
| 2019-12-31 | $10.89 Million | -- |